Human Anti-ERBB2 Recombinant Antibody (clone H2-18) (CAT#: HPAB-0679YY)

Figure 1 H2-18 and GDC-0941 synergistically inhibited the growth of both trastuzumab-sensitive and -resistant breast cancer cell lines.

CCK8 assay was used to compare cell proliferation of the breast cancer cell lines SKBR-3 upon indicated treatments.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Figure 2 H2-18 plus GDC-0941 inhibits the ErbB2 signaling in breast cancer cell lines HCC-1954.

Quantification of Akt phosphorylation in HCC-1954 cells following indicated drug treatments. HCC-1954 cells treated with control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 for 4h were lysed immediately, and the concentrations of phospho-Akt in the cell lysates were determined by a commercially available ELISA kit.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Figure 3 H2-18 and GDC-0941 in combination induced more cell death than agents alone.

Cell death induced by control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 in breast cancer cell line SKBR-3 was examined by flow cytometry using Annexin V/PI double staining detecting kit.

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Figure 4 H2-18 plus GDC-0941 suppressed the in vivo growth of HCC-1954 xenografts.

Tumor volume of HCC-1954 breast tumor xenografts were calculated after treatment with control IgG (10 mg/kg, twice a week, intravenously), H2-18 (10 mg/kg, twice a week, intravenously), GDC-0941 (100 mg/kg, daily, orally), and GDC-0941 (100 mg/kg, daily, orally) plus H2-18 (10 mg/kg, twice a week, intravenously).

Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.

Figure 5 H2-18 potently induces apoptosis in ErbB2-overexpressing breast cancer cell lines.

Cell death induced by control IgG, trastuzumab, pertuzumab, trastuzumab plus pertuzumab, and H2-18 in high-ErbB2-expressing (BT-474) was measured by flow cytometry using Annexin V/PI detecting kit.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Figure 6 H2-18-induced cell death is RIP1-dependent programmed necrosis.

The effect of pan caspase inhibitor Z-VADFMK and autophagy inhibitor bafilomycin A1 on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Figure 7 H2-18-induced cell death is RIP1-dependent programmed necrosis.

TEM images of HCC-1954 cells treated with control IgG, trastuzumab, pertuzumab, pertuzumab plus trastuzumab, and H2-18 for 48 hours.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Figure 8 H2-18-induced cell death is RIP1-dependent programmed necrosis.

The effect of Nec-1 on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Figure 9 ROS and JNK take part in H2-18-induced programmed cell death.

The effect of JNK inhibitor SP600125 or ROS scavenger NAC on H2-18-induced cell death in HCC-1954 cells.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.

Figure 10 ROS and JNK take part in H2-18-induced programmed cell death.

JC-1 staining was used to measure the mitochondrial membrane potential in HCC-1954 cells treated with H2-18.

Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.